Why cancer drug programs need human mass balance studies
Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…
CertaraSeptember 23, 2024
A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule‑1 Biomarker
Discover how PK‑TD modelling shows palonosetron reduces platinum exposure and KIM‑1 elevations versus other antiemetics…
CertaraSeptember 20, 2024
Intravenous Versus Intraosseous Use of Tranexamic Acid in Patients With Traumatic Brain Injury
See how IV and intraosseous TXA show similar total exposure in prehospital TBI care, analysed…
CertaraSeptember 2, 2024
Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome
Learn how triple‑drug combinations increase clobazam metabolite exposure and improve seizure control, modelled using Phoenix…
CertaraAugust 30, 2024
In Vivo Activity of Intestinal P-Glycoprotein and Hepatic Organic Anion Transporters Polypeptide in Pregnancy and Postpartum
Find out how rosuvastatin exposure increases during pregnancy due to reduced OATP activity, while P‑gp…
CertaraAugust 27, 2024
Resmetirom: A pioneering NASH clinical program
Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…
CertaraAugust 23, 2024
Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…
CertaraAugust 19, 2024
